| Autor: |
Cheng X; Target Discovery Institute and.; Ludwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom., Prange-Barczynska M; Target Discovery Institute and.; Ludwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom., Fielding JW; Target Discovery Institute and.; Ludwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom., Zhang M; Target Discovery Institute and., Burrell AL; Francis Crick Institute, London, United Kingdom., Lima JD; Target Discovery Institute and., Eckardt L; Target Discovery Institute and., Argles I; Target Discovery Institute and., Pugh CW; Target Discovery Institute and., Buckler KJ; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom., Robbins PA; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom., Hodson EJ; Francis Crick Institute, London, United Kingdom., Bruick RK; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Collinson LM; Francis Crick Institute, London, United Kingdom., Rastinejad F; Target Discovery Institute and., Bishop T; Target Discovery Institute and., Ratcliffe PJ; Target Discovery Institute and.; Ludwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom.; Francis Crick Institute, London, United Kingdom. |
| Abstrakt: |
Hypoxia-inducible factor (HIF) is strikingly upregulated in many types of cancer, and there is great interest in applying inhibitors of HIF as anticancer therapeutics. The most advanced of these are small molecules that target the HIF-2 isoform through binding the PAS-B domain of HIF-2α. These molecules are undergoing clinical trials with promising results in renal and other cancers where HIF-2 is considered to be driving growth. Nevertheless, a central question remains as to whether such inhibitors affect physiological responses to hypoxia at relevant doses. Here, we show that pharmacological HIF-2α inhibition with PT2385, at doses similar to those reported to inhibit tumor growth, rapidly impaired ventilatory responses to hypoxia, abrogating both ventilatory acclimatization and carotid body cell proliferative responses to sustained hypoxia. Mice carrying a HIF-2α PAS-B S305M mutation that disrupts PT2385 binding, but not dimerization with HIF-1β, did not respond to PT2385, indicating that these effects are on-target. Furthermore, the finding of a hypomorphic ventilatory phenotype in untreated HIF-2α S305M mutant mice suggests a function for the HIF-2α PAS-B domain beyond heterodimerization with HIF-1β. Although PT2385 was well tolerated, the findings indicate the need for caution in patients who are dependent on hypoxic ventilatory drive. |
